MEDP Stock Surges 9.2% With A 8-day Winning Spree On RBC Outperform Rating
Medpace (MEDP) – a clinical research service provider for drug and device development. – hit a 8-day winning streak, with cumulative gains over this period amounting to 9.2%. The company’s market cap has surged by about $1.1 Bil over the last 8 days and currently stands at $14 Bil.
The stock has YTD (year-to-date) return of 14.8% compared to -0.7% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Rally?
[1] RBC Capital Initiates Coverage With ‘Outperform’ Rating
- How To Earn 13% Yield While Waiting to Buy APH 30% Cheaper
- Cash Machine Trading Cheap – Adobe Stock Set to Run?
- Walmart Stock Hands $76 Bil Back – Worth a Look?
- UnitedHealth Stock Shares $77 Bil Success With Investors
- Years of Rewards: $57 Bil From Pfizer Stock
- Norwegian Cruise Line Stock Hits Key Support – Buying Opportunity?
- New ‘Outperform’ rating issued
- Price target set at $522.00
- Impact: Strengthened investor conviction, Continuation of positive price momentum
[2] Strong Q4 2025 Earnings Beat & Positive Analyst Actions
- Beat EPS estimates by $0.49
- Jefferies upgrade to ‘Buy’ with $560 target
- Impact: Initial surge following earnings release, Improved institutional sentiment
Opportunity or Trap?
Below is our take on valuation.
There is not much to fear in MEDP stock given its overall Strong operating performance and financial condition. This is aligned with the stock’s High valuation because of which we think it is Fairly Priced (For details, see Buy or Sell MEDP).
But here is the real interesting point.
You are reading about this 9.2% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that have not surged yet.
Returns vs S&P 500
The following table summarizes the return for MEDP stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | MEDP | S&P 500 |
|---|---|---|
| 1D | 1.7% | 0.8% |
| 8D (Current Streak) | 9.2% | -2.2% |
| 1M (21D) | -11.6% | -0.0% |
| 3M (63D) | -12.2% | -0.9% |
| YTD 2026 | -14.8% | -0.7% |
| 2025 | 69.1% | 16.4% |
| 2024 | 8.4% | 23.3% |
| 2023 | 44.3% | 24.2% |
However, big gains can follow sharp reversals – but how has MEDP behaved after prior drops? See MEDP Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 14 S&P constituents with 3 days or more of consecutive gains and 99 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 6 | 53 |
| 4D | 3 | 7 |
| 5D | 2 | 16 |
| 6D | 3 | 16 |
| 7D or more | 0 | 7 |
| Total >=3 D | 14 | 99 |
Key Financials for Medpace (MEDP)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $2.1 Bil | $2.5 Bil |
| Operating Income | $446.9 Mil | $534.9 Mil |
| Net Income | $404.4 Mil | $451.1 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $659.9 Mil | $708.5 Mil |
| Operating Income | $141.8 Mil | $153.3 Mil |
| Net Income | $111.1 Mil | $135.1 Mil |
While MEDP stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.